Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611325 | 0.91 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL5611334 | 0.91 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL8085681 | 0.91 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL9239993 | 0.83 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL6061013 | 0.83 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL6061014 | 0.83 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL15499936 | 0.82 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2ATMGFPT1 | |
| SCHEMBL15512022 | 0.82 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2ATMGFPT1 | |
| SCHEMBL9242308 | 0.81 | HCAR2 (0.54) | HCAR2KEAP1NFE2L2ATMGFPT1 | |
| SCHEMBL4926884 | 0.81 | HCAR2 (0.57) | HCAR2KEAP1NFE2L2ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9932294-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-04-03 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9499526-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9434704-B2 | Compositions and methods for the treatment of neurological degenerative disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-09-06 | — | — | US | disclosed |
| US-9434729-B2 | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis | CELLIX BIO PRIVATE LIMITED (IN) | 2016-09-06 | — | — | US | disclosed |
| US-20160152553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-02 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141513-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2015-05-21 | — | — | US | disclosed |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20150119424-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119424-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150111932-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS | RORC, IL17A, PTGER1 | HCAR2 359/4885KEAP1 4036/4885NFE2L2 3567/4885 |
| US-20160152553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | HLA-DRB1, SI, PMP22 | HCAR2 697/4885KEAP1 2114/4885NFE2L2 1945/4885 |
| US-20150141513-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES | TARDBP, CHAT, COMT | HCAR2 1180/4885KEAP1 608/4885NFE2L2 1147/4885 |
| US-20150119424-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES | SLC6A11, SCN1A, PSEN1 | HCAR2 1421/4885KEAP1 1254/4885NFE2L2 2484/4885 |
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | PYGB, PSEN1, SI | HCAR2 2404/4885KEAP1 1481/4885NFE2L2 2073/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | HCAR2 354/4885KEAP1 1819/4885NFE2L2 1683/4885 |
| US-20150111932-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | LPXN, HNRNPU, KYNU | HCAR2 1984/4885KEAP1 1917/4885NFE2L2 1281/4885 |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | SORD, MUC1, CFTR | HCAR2 933/4885KEAP1 705/4885NFE2L2 2404/4885 |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | PSEN1, APP, PSEN2 | HCAR2 1344/4885KEAP1 1618/4885NFE2L2 1882/4885 |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | HTT, SNCA, PARK7 | HCAR2 2199/4885KEAP1 362/4885NFE2L2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.